Diagnostic firm receives $7 million to advance novel Alzheimer’s biomarker platform
Click Here to Manage Email Alerts
C2N Diagnostics has been awarded more than $7 million from the Alzheimer’s Drug Discovery Foundation’s Diagnostics Accelerator initiative to advance a novel platform intended to boost Alzheimer’s disease biomarker detection.
In a press release, C2N Diagnostics revealed the funding will be utilized to create a fully automated, standardized, high-resolution liquid chromatography-mass spectrometry (LC-MS) platform that tracks both amyloid and tau pathology and lays the groundwork for adding potential assays targeting different measures of neuropathology.
Created in 2018, Diagnostics Accelerator is a global research initiative joining a range of concerned parties from the business, medical and philanthropic worlds.
C2N’s PrecivityAD2 blood test, the development of which was supported by a $15 million award in February 2023, is expected to benefit from the platform’s creation and expansion.
“Early and accurate detection represents the greatest chance for transforming the trajectory of Alzheimer’s disease through early treatment and prevention,” C2N CEO Joel Braunstein, MD, MBA, stated in the release. “We thank the Diagnostics Accelerator for their trust and confidence in our approach. This project aims to truly redefine what it means to offer high-performance Alzheimer’s disease testing on a global scale.”
According to statistics cited in the release, JAMA published research that showed the company’s PrecivityAD2 test delivered 90% accuracy at a pre-defined, single binary cutoff compared with cerebrospinal fluid or amyloid PET analysis.
“Blood tests are transforming Alzheimer’s disease detection and will continue to play a critical role in the future of Alzheimer’s treatment and research,” Howard Fillit, MD, co-founder and chief science officer at Alzheimer’s Drug Discovery Foundation, said in a related release.
In the Alzheimer’s Drug Discovery Foundation release, Fillit additionally acknowledged that PrecivityAD2’s pTau217 test has emerged as the “gold standard” in blood-based biomarker diagnostics, with a high degree of sensitivity and accuracy that likely will replace invasive PET scans and spinal taps.
References:
- Alzheimer’s Drug Discovery Foundation’s Diagnostics Accelerator (DxA) invests more than $7 million in C2N Diagnostics’ blood tests. Available at: https://www.alzdiscovery.org/news-room/announcements/alzheimers-drug-discovery-foundations-diagnostics-accelerator-dxa-invests-more-than-7-million-in-c2n-diagnostics-blood-tests. Published Sept. 25, 2024. Accessed Sept. 26, 2024.
- CRN receives funding from Diagnostics Accelerator to develop a decentralized clinical mass spectrometry solution to enable high-performance Alzheimer’s disease testing worldwide. Available at: https://c2n.com/news-releases/c2n-receives-funding-from-diagnostics-accelerator-to-develop-a-decentralized-clinical-mass-spectrometry-solution-to-enable-high-performance-alzheimers-disease-testing-worldwide. Published Sept. 25, 2024. Accessed Sept. 26, 2024.